ClinicalTrials.gg
RecruitingNCT05992311(GWI)Updated Sep 1, 2026

Clinical Evaluation of Montelukast in Veterans With Gulf War Illness

A Phase 1 interventional study of Montelukast and Placebo in Gulf War Syndrome, sponsored by Baylor College of Medicine. Recruiting at 1 site in United States. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Baylor College of Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Persian Gulf Syndrome with a site in United States — 9 open to participants now, 9 under way, 1 of them phase 3. Persian Gulf Syndrome · United States.

Planned enrollment
12th of 31
80 · median 53
Started
2025
with 2 others
Phase 1
5 of 41
2 open now
Registered
37th of 41
by date
Lead sponsor
3 of 41
Baylor College of Medicine

Among the 41 studies in Persian Gulf Syndrome with a site in United States, this one is the 12th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 37th registered.

Persian Gulf Syndrome

41 studies on the registry are indexed under Persian Gulf Syndrome; 9 are open to participants now.

Browse Persian Gulf Syndrome studies →

Open to participants now

9 of the 41 studies in Persian Gulf Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Persian Gulf Syndrome studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Persian Gulf Syndrome with a site in United States, or all of them as a file.
02

Study summary

The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.

Read the detailed description

Background: Approximately 30% of Gulf War Veterans (1990-1991) suffer from Gulf War Illness (GWI), a chronic condition characterized by disabling symptoms in multiple domains. Animal models and human data suggest a prominent neuroinflammatory basis for many of the symptoms of GWI. Preliminary data from an established GWI rat model demonstrates the involvement of increased leukotriene signaling in the brain and its potential as a marker of neuroinflammation when detected in neuron- and astrocyte-derived extracellular vesicles present in the peripheral blood. MLK, an FDA-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation. MLK has a strong safety record and has been recognized for its potential as a modulator of neurodegeneration in human disease and is, therefore, a promising intervention for GWI.

Hypothesis/Objective: Examine the impact of MLK on cognition, quality of life, and symptoms of depression and anxiety in Veterans with GWI and test for changes in brain-specific leukotrienes (markers of neuroinflammation) detectable in the extracellular vesicles circulating in the peripheral blood.

Specific Aim 1: To evaluate the effect of MLK on cognitive function, functional status and mood in veterans with GWI using validated neurocognitive and self-reported measures consistent with the GWI Common Data Elements.

Specific Aim 2: To examine the antiinflammatory effects of MLK on the brain. The investigators will evaluate neuron-derived extracellular vesicles and astrocyte-derived extracellular vesicles in blood samples from Veterans with GWI receiving MLK or placebo treatment.

Study Design: 1:1 randomized, double-blind, placebo controlled trial of 80 Veterans who meet both the Kansas and Center for Disease Control (CDC) definition of GWI and report cognitive dysfunction treated with either: 1) two capsules of 20 mg of MLK or 2) two capsules of matched placebo taken daily for 10 weeks. Participants will be recruited to participate at Michael E. DeBakey VA Medical Center (MEDVAMC) in Houston, TX, using best practices including Veteran community outreach and engagement, active recruitment from local and national VA databases, and a strong social media presence. Participants will be screened for eligibility by phone and attend only two in-person evaluations (self-reported instruments, blood draw, and neuropsychology tests) with regular phone contact throughout study enrollment. Blood specimens will be obtained, and plasma processed at MEDVAMC, and shipped to Texas A\&M University College of Medicine (TAMU-COM) for specialized assays. Data will be maintained, managed and analyzed by the MEDVAMC team in collaboration with the TAMU team.

Impact: The findings from the proposed research will advance the understanding of the pathophysiology, validate the use of extracellular vesicle assays as a biomarker of central nervous system inflammation, and advance a potential treatment (i.e., MLK) for a specific putative underlying mechanism of GWI. The short-term impact will be an important validation of the theory of neuroinflammation as central pathophysiology of GWI through the tested hypotheses. The longer-term impact of the proposed work includes a relatively short timeline to the use of MLK as a specific treatment for GWI. Because MLK is already FDA approved and safe, if findings from this project support the safety, tolerability, and efficacy of MLK in Veterans with GWI, a definitive randomized controlled trial confirming its efficacy would be warranted.

03

Conditions studied

  • Gulf War Syndrome

Browse trials for

Keywords

  • Montelukast
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gulf War Veterans of the U.S. military deployed on military orders to the Persian Gulf Region between August 2, 1990, and December 31, 1991
  • Diagnosed with GWI according to the CDC and modified Kansas criteria as recommended by the Institute of Medicine (IOM), that is, endorse multiple or moderate-to-severe symptoms, with symptom onset during or after deployment to the Persian Gulf region in 1990-1991, persisting for six months or longer, in at least 3 of 6 domains:

    1. fatigue/sleep disturbances
    2. neurological/cognitive/mood symptoms
    3. somatic pain
    4. gastrointestinal problems
    5. respiratory symptoms
    6. skin symptoms
  • Self-reported cognitive dysfunction based on a T-score of 40 or less on the PROMIS v2.0 Cognitive Function 8a short form
  • Be able to:

    • provide written consent and be able to communicate with the research team in verbal and written English
    • attend the two in-person study encounters
    • have reliable telephone service for the eight weekly telephone encounters

Exclusion criteria

Exclusion Criteria:

  • Diagnosed by a physician with any chronic condition that may explain their profile of symptoms or prevent their ability to accurately report them including:

    • chronic conditions
    • systemic inflammatory conditions
    • cancer not in remission at least 5 years
    • congestive heart failure
    • anemia
    • multiple sclerosis
    • amyotrophic lateral sclerosis (ALS)
    • poorly controlled diabetes
    • post-chemo or radiation syndromes
    • sickle cell anemia
    • symptomatic Coronary Artery Disease (CAD)
    • chronic liver disease
    • chemical insufficiency
    • morbid obesity ( (BMI) >= 40)
    • (HIV)
    • alcohol/substance use disorder/stimulant/opioid/other depressant misuse in the past year
    • major mental health condition (e.g., psychosis, suicidal ideations, major depressive disorder) that interferes with their ability to accurately report symptoms
    • hospitalized or undergoing invasive procedures in the past 12 months due to exacerbations of any chronic conditions (such as diabetes, coronary artery disease, hypertension, or emphysema)
    • elevated liver enzymes (2.5 times ) at baseline visit
    • estimated less than 60 ml/min/1.73 sqm at baseline visit
    • less than 10 g/L at baseline visit
    • evidence of poorly controlled chronic conditions listed above, or others that may mimic GWI as per the PI, either by self-report, Veterans Health Administration (VHA) electronic health record information review, laboratory testing or physical examination
  • Changes in medications for chronic conditions in the 3 months preceding enrollment (based on self-report)
  • Suicidal ideation based on their responses on the Columbia Suicide Risk Inventory
  • Prescribed or taking Montelukast in the past 6 months for any reason
  • Taking 2 or more medications with moderate interactions with Montelukast
  • Pregnancy or intention to become pregnant
  • Active homicidal ideation
  • COVID-19 illness (confirmed or suspected) without recovery to pre-COVID health status
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Montelukast Group

    Montelukast two capsules of 20 mg (40 mg total) taken by mouth once daily for ten weeks

    Drug: Montelukast

  • Placebo comparator
    Placebo Group

    Microcrystalline cellulose two capsules taken by mouth once daily for ten weeks

    Other: Placebo

Interventions

  • This group will receive the montelukast treatment.

    Also known as: Singulair

  • OtherPlacebo

    This group will receive a placebo pill instead of montelukast

06

What researchers measure

Primary outcomes

  1. Leukotriene concentration

    Concentrations in the brain-derived extracellular vesicles collected from the circulating peripheral blood.

    Time frame: taken at baseline (week 0) and after the intervention (week 10)

Secondary outcomes

  1. Change in RCAT (Halstead Category Test-Russell Revised Version)

    Instrument designed to measure cognitive function. Scores are reported as T-scores while participant's age, gender, ethnicity, and level of education are controlled. A higher T-score correlates to better executive functioning.

    Time frame: taken at baseline (week 0) and after the intervention (week 10)

  2. Change in Veterans Rand-36 Physical Component Summary (VR-36 PCS) score

    Scores reflect physical health-related quality of life. The scores are reported on a scale 0-100 with 0 being the worst possible score and 100 being the best possible score. The mean score of the US population is 50.

    Time frame: taken at baseline (week 0) and after the intervention (week 10)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 15, 2023
StartActual
Aug 15, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Aug 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05992311
Collaborators
Michael E. DeBakey VA Medical Center, Texas A&M University
Responsible party
Drew Helmer (Professor, Baylor College of Medicine) — Principal investigator
First posted
Aug 15, 2023
Start date
Aug 15, 2025
Primary completion
Apr 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Jason K Aguilar, BA
Contact
jason.aguilar@va.gov
713-440-4633
Kandice Motley, BS
Contact
kandice.motley@bcm.edu
713-440-4445
Drew A Helmer, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Montelukast

Start the discussion